Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy

Fig. 5

PDIA4 facilitated GBM growth, poor prognosis, and angiogenesis in vivo. A In vivo xenograft U87 GBM tumors were imaged at 7, 14, 21, and 28 days after the intracranial tumor was implanted using the IVIS system. B Representative HE staining images show the distinct size of xenograft U87 GBM with different PDIA4 expression. C The line chart shows the weight variation of GBM-bearing nude mice in two groups. **P < 0.01. D Recorded total flux at each time point indicates growing xenograft tumor size of each nude mice group dynamically. **P < 0.01. E Kaplan–Meier survival analysis showed nude mice with overexpression PDIA4 xenograft had poorer outcomes. F Representative VEGFA IHC images in two mice groups. G IHC scores of VEGFA in high-PDIA4 xenograft GBMs are significantly higher than low-PDIA4 xenograft GBMs. **P < 0.01. H Representative CD31 IHC images in two mice groups. I CD31-positive cell number in high-PDIA4 xenograft GBMs are significantly higher than low-PDIA4 xenograft GBMs. **P < 0.01. J Immunofluorescence of PDIA4 (green), CD31 (red) and DAPI (blue) in three cases of GBM samples

Back to article page